10x Genomics CEO Calls NIH The 'Foundational Jewel' Of Biomedical Progress, Says 40% To 50% Of Revenue Supported By Academic And Government Research Funding — Pulls Full Year Revenue Guidance

During its first-quarter earnings call on Thursday, 10x Genomics Inc. (NASDAQ:TXG) withdrew its full-year guidance, opting instead to provide quarterly forecasts. What Happened: The company cited policy uncertainty stemming from recent U.S. government budget cuts for academic research as the…